Expertise in
15
conditions

Dr. Christina I. Tsien

Radiation Oncology
Washington University School Of Medicine
4921 Parkview Pl, 
Saint Louis, MO 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
15
conditions
Washington University School Of Medicine
4921 Parkview Pl, 
Saint Louis, MO 

Overview

Christina Tsien is a Radiation Oncologist practicing medicine in Saint Louis, Missouri.

Dr. Tsien is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Glioma, Gliomatosis Cerebri, Glioblastoma, Gastrostomy, and Gamma Knife Radiosurgery.

She is actively involved in clinical research, co-authoring 111 peer reviewed articles and participating in 14 clinical trials.

Specialties

Radiation Oncology

Licenses

Radiology in MO

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Washington University School of Medicine
4921 Parkview Pl, Saint Louis, MO 63110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Enrollment Status: Recruiting
Publish Date: June 25, 2026
Intervention Type: Other, Procedure, Radiation
Study Phase: Phase 3
A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas
A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Temozolomide
Study Phase: Phase 2
A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized in Patients With Newly Diagnosed, Unmethylated Glioblastoma
A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2026
Intervention Type: Device, Biological, Drug
Study Drugs: Personalized neoantigen DNA vaccine, Plasmid encoded IL-12
Study Phase: Phase 1
Effect of rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide
Effect of rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Drug, Radiation
Study Drugs: rhIL-7-hyFc, Temozolomide
Study Phase: Phase 1/Phase 2
Safety and Efficacy Study of Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Safety and Efficacy Study of Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Enrollment Status: Completed
Publish Date: November 21, 2025
Intervention Type: Drug, Radiation
Study Drugs: Epacadostat, Bevacizumab
Study Phase: Phase 2
A Phase I/II Dose-escalation and Dose-expansion Study of Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
A Phase I/II Dose-escalation and Dose-expansion Study of Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: April 10, 2025
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Disulfiram, Copper Gluconate, Temozolomide
Study Phase: Phase 1/Phase 2
A Phase Ib Study of Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma
A Phase Ib Study of Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma
Enrollment Status: Terminated
Publish Date: June 15, 2023
Intervention Type: Radiation, Drug, Procedure
Study Drug: Avelumab
Study Phase: Phase 1
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
Enrollment Status: Completed
Publish Date: May 11, 2023
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Depatuxizumab
Study Phase: Phase 3
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Enrollment Status: Terminated
Publish Date: March 23, 2023
Intervention Type: Drug, Other
Study Phase: Phase 2
A Phase 1 Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases (BRAINSTORM)
A Phase 1 Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases (BRAINSTORM)
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Drug: RRx-001
Study Phase: Phase 1
View 9 Less Clinical Trials

111 Total Publications

Neoadjuvant Capecitabine in Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck.
Neoadjuvant Capecitabine in Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck.
Journal: JAMA dermatology
Published: May 27, 2026
Similar Doctors
Expertise in
15
conditions
Dr. Perry W. Grigsby
Radiation Oncology
Expertise in
15
conditions
Dr. Perry W. Grigsby
Radiation Oncology
Referral may be required

Barnes Hospital Washington University

510 S Kingshighway Blvd, 
Saint Louis, MO 
 (0.2 miles away)
Languages Spoken:
English
See accepted insurances

Perry Grigsby is a Radiation Oncologist practicing medicine in Saint Louis, Missouri. Dr. Grigsby is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Cervical Cancer, Thyroid Cancer, Papillary Thyroid Cancer, Follicular Thyroid Cancer, and Thyroidectomy.

Expertise in
26
conditions
Dr. Clifford G. Robinson
Radiation Oncology
Expertise in
26
conditions
Dr. Clifford G. Robinson
Radiation Oncology
Referral may be required

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (0.1 miles away)
314-747-7236
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Clifford Robinson is a Radiation Oncologist practicing medicine in Saint Louis, Missouri. Dr. Robinson is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma. Dr. Robinson is currently accepting new patients.

Expertise in
6
conditions
Dr. Jeff M. Michalski
Radiation Oncology
Expertise in
6
conditions
Dr. Jeff M. Michalski
Radiation Oncology
Referral may be required

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (0.1 miles away)
314-747-7236
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients

Jeff Michalski is a Radiation Oncologist practicing medicine in Saint Louis, Missouri. Dr. Michalski is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, Angiosarcoma, and Prostatectomy. Dr. Michalski is currently accepting new patients.

Frequently Asked Questions about Dr. Christina I. Tsien

How do I make an appointment with Dr. Christina I. Tsien?

You can book an appointment with Dr. Christina I. Tsien by calling their office at 314-747-7236. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Christina I. Tsien a top-rated expert for Glioma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Christina I. Tsien is classified as an Distinguished expert for Glioma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Christina I. Tsien specialize in?

While Dr. Christina I. Tsien is a Radiation Oncology, they have specific expertise in Glioma, Gliomatosis Cerebri, and Glioblastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Christina I. Tsien participate in research or clinical trials?

Yes. Dr. Christina I. Tsien has published 111 articles and abstracts on conditions like Glioma. You can view a list of Dr. Christina I. Tsien's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Christina I. Tsien accept my insurance?

Dr. Christina I. Tsien accepts most major insurance plans, including Humana. We recommend calling the office directly at 314-747-7236 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tsien's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile